Table 1. Patient characteristics.
| Characteristics | All Patients (n = 622) | Invasive cancer (n = 530) | Carcinoma in situ (n = 92) |
|---|---|---|---|
| Age at diagnosis | |||
| Median(range) | 45(21–78) | 45.5(21–78) | 45(25–64) |
| Primary histology (n) | |||
| Carcinoma in situ | 92 | ||
| IDC | 494 (93.2) | ||
| Others histology | 36 (6.8) | ||
| Breast side | |||
| Left | 304 (48.9) | 269 (50.7) | 35 (38) |
| Right | 318 (51.1) | 261 (49.3) | 57 (62) |
| T stage | |||
| Tis | 92 (14.8) | 92 (100) | |
| T1 | 367 (59) | 367 (69.2) | |
| T2 | 146 (23.5) | 146 (27.5) | |
| unknown | 17 (2.7) | 17 (3.2) | |
| Sentinel node sampled (n) | |||
| Median (range) | 3 (1–8) | 3 (1–6) | |
| Lymph node clearance (n) | |||
| Median (range) | 16 (2–41) | 0 (0–23) | |
| N stage | |||
| N0 | 435 (69.9) | 383 (72.2) | 52 (56.5) |
| N+ | 147 (23.6) | 147 (27.7) | |
| Nx | 40 (6.4) | 40 (43.5) | |
| ER status | |||
| Positive | 454 (73.0) | 385 (72.6) | 69 (75) |
| Negative | 162 (26.0) | 142 (26.8) | 20 (21.7) |
| Unkown | 6 (1.0) | 3 (0.5) | 3 (3.3) |
| PR status | |||
| Positive | 433 (69.6) | 368 (69.4) | 65 (70.6) |
| Negative | 184 (29.6) | 160 (30.2) | 24 (26.1) |
| unkown | 5 (0.5) | 2 (0.4) | 3 (3.3) |
| HER2 status | |||
| Positive | 93 (17.5) | 7 (9.6) | |
| Negative | 434 (81.8) | 82 (89.1) | |
| unknown | 5 (0.7) | 3 (3.3) | |
| Molecular subtype | |||
| Luminal | 400 (75.5) | ||
| Triple negative | 90 (17.0) | ||
| HER2 enriched | 38 (7.1) | ||
| Unknown | 2 (0.4) | ||
| Grade | |||
| I-II | 398 | 317 (59.8) | 72 (78.2) |
| III | 161 | 147 (27.7) | 12 (13.0) |
| unkown | 75 | 66 (12.5) | 8 (8.7) |
| LVI | |||
| Positive | 81 (15.3) | ||
| Negative | 344 (64.9) | ||
| unkown | 105 (19.8) | ||
| Margin | |||
| Positive/close | 12 (1.9%) | 11 (2.1) | 1 (1) |
| Negative | 582 (93.5) | 499 (94.2) | 83 (90.2) |
| Unkown | 28 (4.5%) | 20 (3.8) | 8 (8.7) |
| Endocrine therapy | 482 | 406 | 76 |
| Chemotherapy | 470 | 446 | 24 |
| Trastuzumab | 51 | 51 | 0 |
| Radiotherapy | |||
| Breast only | 490 (78.8) | 398 | 92 |
| Breast + RLN | 132 (21.2) | 132 | 0 |
Abbreviation: Nx lymph node not be evaluated; IDC invasive ductal carcinoma; LVI lymphovascular invasion